Kronik Böbrek Hastalığında Anemi Yönetimi
Özet
Kronik böbrek hastalığı (KBH), küresel ölçekte ve ülkemizde yüksek prevalans gösteren, evre ilerledikçe sıklığı artan anemi komplikasyonu ile karakterize hayati bir sağlık sorunudur. Renal anemi, hastaların genel yaşam kalitesini düşürmekle kalmayıp sol ventrikül hipertrofisi ve kalp yetmezliği gibi ciddi kardiyovasküler morbidite ve mortalite risklerini beraberinde getirmektedir. Bu tablonun gelişimindeki temel fizyopatolojik mekanizmalar arasında yetersiz eritropoietin (EPO) üretimi, kronik inflamasyon süreçlerinin tetiklediği artmış hepsidin seviyeleri ve buna bağlı gelişen fonksiyonel demir homeostazı bozuklukları yer almaktadır. Tedavi yaklaşımında mutlak ve fonksiyonel demir eksikliğinin transferrin satürasyonu (TSAT) ve ferritin parametreleri ile doğru ayrımı kritik bir öneme sahiptir. Güncel anemi yönetimi, kan transfüzyon ihtiyacını en aza indirmeyi ve ESA dozunu optimize etmeyi hedeflerken; geleneksel oral veya intravenöz demir tedavilerinin yanı sıra yeni nesil modern demir preparatlarını, uzun etkili eritropoezi uyarıcı ajanları (ESA) ve yenilikçi hipoksi ile indüklenebilir faktör prolil hidroksilaz inhibitörlerini (HIF-PHI) klinik pratiğe entegre etmektedir. Ayrıca, gelecekte tedavi başarısını daha da artırması öngörülen hepsidin modülatörleri, GATA-2 ve SGLT2 inhibitörleri gibi yeni nesil moleküler yaklaşımlar, KBH hastalarında anemi yönetiminin gelecekteki stratejik rotasını çizmektedir.
Chronic kidney disease (CKD) constitutes a critical global health concern characterized by a high prevalence of anemia, which escalates dramatically alongside the progression of renal insufficiency. This manifestation severely impairs the patient's quality of life and accelerates severe cardiovascular complications, ultimately resulting in heightened morbidity and clinical mortality rates. The intricate pathophysiology of renal anemia primarily involves a relative deficiency in erythropoietin (EPO) production, elevated hepcidin levels driven by systemic chronic inflammation, and subsequent disruptions in functional iron homeostasis. Consequently, accurate diagnostic evaluation requires distinguishing between absolute and functional iron deficiencies through systematic monitoring of ferritin and transferrin saturation (TSAT) levels. Contemporary clinical management models prioritize mitigating blood transfusion reliance and optimizing therapeutic outcomes by leveraging next-generation oral or intravenous iron formulations, long-acting erythropoiesis-stimulating agents (ESAs), and innovative hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). Looking forward, novel molecular interventions, including advanced hepcidin modulators, GATA-2 inhibitors, and SGLT2 inhibitors, are poised to fundamentally reshape the clinical landscape, offering optimized efficacy and enhanced safety profiles for renal anemia management.
Referanslar
Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease – A systematic review and meta-analysis. PLoS One 2016; 11. doi: 10.1371/journal.pone.0158765.
Süleymanlar G, Utaş C, Arınsoy T, et al. A population based survey of chronic renal disease in Turkey - The CREDIT study. Nephrology, Dialysis,Transplantation. 2011; 26: 1862-71. doi: 10.1093/ndt/gfq656.
Hanna M.R, Streja E, Kalantar-Zadeh K. Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. Advances in Therapy. 2021; 38(1): 52–75. doi: 10.1007/s12325-020-01524-6.
El-Achkar TM, Ohmit SE, McCullough PA, et al. Higher prevalence of anaemia with diabetes mellitus in moderate kidney insufficiency: the kidney early evaluation program. Kidney İnternational. 2005 ; 67:1483–1488.doi: 10.1111/j.15231755.2005.00226.x.
McLean E, Cogswell M, Egli I, et al. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutrition. 2009;12:444–454. doi: 10.1017/S1368980008002401.
Rao M, Pereira BJ. Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney International. 2005;68:1432–1438.
Mukhopadhyay P, Sinha U, Banerjee J, et al. The effects in correction of anaemia in chronic kidney disease with erythropoietin therapy–preference to cardiovascular, neurologic and general well-being of patients from a tertiary care centre. Journal of the Indian Medical Association. 2012;110:885–888.
Babitt J, Lin H.Y. Mechanisms of anemia in CKD. Journal of the American Society of Nephrology. 2012;23:1631–1634. doi: 10.1681/ASN.2011111078.
Batchelor E.K, Kapitsinou P, Pergola P.E, et al. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. Journal of American Society of Nephrology. 2020;31:456–468.doi: 10.1681/ASN.2019020213.
Zaritsky J, Young B, Wang H.J, et al. Hepcidin-A potential novel biomarker for iron status in chronic kidney disease. Clinical Journel American Society of Nephrology. 2009;4:1051–1056. doi: 10.2215/CJN.05931108.
Suzuki N, Gradin K, Poellinger L, et al. Regulation of hypoxia-inducible gene expression after HIF activation. Experimental Cell Resarch. 2017;356:182186.doi: 10.1016/j.yexcr.2017.03.013.
Jelkmann W. Molecular biology of erythropoietin. Internal Medicine (Tokyo,Japan).2004;43(8):649-659. doi:10.2169/internalmedicine.43.649.
Bissinger R, Artunc F, Qadri S. M, et al. Reduced erythrocyte survival in uremic patients under hemodialysis or peritoneal dialys. Kidney Blood Pressure Research. 2016;41(6):966-977.doi: 10.1159/000452600
Dias G. F, Bonan N. B, Steiner T. M, et al. (2018). Indoxyl sulfate, a uremic toxin, stimulates reactive oxygen species production and erythrocyte cell death supposedly by an organic anion transporter 2 (OAT2) and NADPH oxidase activity-dependent pathways. Toxins. 2018 Jul 5;10(7):280. doi: 10.3390/toxins10070280.
Tanaka M, Komaba H, Fukagawa M. Emerging association between parathyroid hormone and anemia in hemodialysis patients. Therapeutic Apheresis and Dialysis. 2018 Jun;22(3):242-245. doi: 10.1111/1744-9987.12685.2018;22:242–245.
Fishman S.M, Christian P, West K.P. The role of vitamins in the prevention and control of anaemia. Public Health Nutrition 2000;3:125–150.doi: 10.1017/S1368980000000173.
Balla S., Ismail A. Impact of Hemodialysis on Serum Zinc and Copper Level in CKD Patients. Journal of Applied Pharmaceutical Science 2016;6:165–168.doi: 10.7324/JAPS.2016.60423.
Pérez G, Pregi N, Vittori D, et al. Aluminum exposure affects transferrin-dependent and -independent iron uptake by K562 cells. Biochimica et BiophysicaActa. 2005; 1745:124–130.doi: 10.1016/j.bbamcr.2004.12.002.
Moreb J, Popovtzer M.M, Friedlaender M.M, et al.Evaluation of iron status in patients on chronic hemodialysis: relative usefulness of bone marrow hemosiderin, serum ferritin, transferrin saturation, mean corpuscular volume and red cell protoporphyrin. Nephron. 1983; 35: 196-200 1983;35(3):196-200.doi: 10.1159/000183074
Locatelli F, Bárány P, Covic A, et al. ERA-EDTA ERBP Advisory Board: Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement. Nephrology, Dialysis, Transplantation. 2013 Jun;28(6):1346-1359. doi: 10.1093/ndt/gft033.
Phiri K.S, Calis J.C, Kachala D, et al. Improved method for assessing iron stores in the bone marrow. Journel Clinical Pathology. 2009; 62: 685-668 https://doi.org/10.1136/jcp.2009.064451
Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney International.2004 Mar;65(3):1091-8. doi: 10.1111/j.1523-1755.2004.00480.x.
KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2:279–335.
Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrology [PMC free artic 2017 Nov 30;18(1):345.doi: 10.1186/s12882-017-0688-1.le]
(NICE) NI for H and CE . Chronic Kidney Disease: Managing Anaemia. (2015). Available online at: nice.org.uk/guidance/ng8 (accessed March 11, 2021).
Pergola P.E, Fishbane S, Ganz T. Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease. Adv. Chronic Kidney Dis. 2019;26:272–291. doi: 10.1053/j.ackd.2019.05.002.
Barraclough K.A, Brown F, Hawley C.M, et al. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. Nephrology, Dialysis, Transplantation. 2012;27:4146–4153. doi: 10.1093/ndt/gfs372.
Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clinical Journal of the American Society of Nephrology. 2014 Mar;9(3):543-52. doi: 10.2215/CJN.05170513.
Kassianides X, Bhandari S. Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review. Drug in Context. 2021 Jan 19;10:2020-11-3. doi: 10.7573/dic.2020-11-3.
Pratt RD. Ferric pyrophosphate citrate injection: no clinical drug interaction with unfractionated heparin in hemodialysis patients [abstract]. In: Kidney Week 2020 Reimagined Abstracts. American Society of Nephrology; 2020:B6-B7. Abstract PO2631.
Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. The American Journal of Medicine. 2012 Oct;125(10):991-999. doi: 10.1016/j.amjmed.2012.01.015.
Kang H, Han M, Xue J. et al. Renal clearable nanochelators for iron overload therapy. Nature Communications. 2019;10:5134. doi: 10.1038/s41467-019-13143-z.
Mc Causland FR, Claggett B, Burdmann EA, et al. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases 2019 Mar;73(3):309-315. doi: 10.1053/j.ajkd.2018.10.006.
Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. The New England Journal of Medicine 2009;361(21):2019-32 doi: 10.1056/NEJMoa0907845.
Locatelli F, Del Vecchio L, De Nicola L, et al. Are all erythropoiesis-stimulating agents created equal? Nephrology, Dialysis, Transplantation.2021Jul 23;36(8):1369-1377.doi: 10.1093/ndt/gfaa034.
Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving haemodialysis. Department of Veterans Affairs Cooperative Study Group on erythropoietin in Haemodialysis patients. The New England Journal of Medicine.1998 Aug 27;339(9):578583. doi:10.1056/NEJM199808273390902.
Johnson D.W, Pollock C.A, Macdougall I.C. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology. 2007 Aug;12(4):321-30. doi: 10.1111/j.1440-1797.2007.00810.x.
Agarwal R. Mechanisms and mediators of hypertension induced by erythropoietin and related molecules. Nephrology, Dialysis, Transplantation. 2018 Oct 1;33(10):1690-1698.doi: 10.1093/ndt/gfx324.
Edmunds M.E, Walls J, Tucker B, et al. Seizures in hemodialysis patients treated with recombinant human erythropoietin. Nephrology, Dialysis, Transplantation.1989;4(12):1065-1069.
Buur T, Lundberg M. Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients. Clinical Nephrology. 1990 Nov;34(5):230-5.
Humphries JE. Anemia of renal failure: Use of erythropoietin. Medical Clinics of North America. 1992;76(3):711-25
Padhi S, Behera G, Pattnaik SA, et al. Acquired Pure Red Cell Aplasia Following Recombinant Erythropoietin ( Darbepoetin-alfa) Therapy. İndian Journal of Nephrology 2022; 30(2):113
Wen T, Zhang X, Wang Z, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with renal anemia: A meta-analysis of randomized trials. Nephron. 2020;144(11):572-582. doi: 10.1159/000508812.
Liu Q, Davidoff O, Niss K, et al. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. The Journal of Clinical. Investigation. 2012 Dec;122(12):4635-44. doi: 10.1172/JCI63924.
Holdstock L, Meadowcroft AM, Maier R, et al. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. Journal of the American Society of Nephrology. 2016;27(4):1234–1244.
Hwang S, Nguyen AD, Jo Y, et al. Hypoxia-inducible factor 1alpha activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. The Journal of Biological Chemistry. 2017 Jun 2;292(22):9382-9393. doi: 10.1074/jbc.M117.788562.
Sanghani N.S, Haase V.H. Hypoxia-inducible factor activators in renal anemia: Current clinical experience.Advances in Chronic Kidney Disease. 2019 Jul;26(4):253-266. doi: 10.1053/j.ackd.2019.04.004.
Katsarou A, Pantopoulos K. Hepcidin Therapeutics .Pharmaceuticals. 2018, 11(4), 27; doi:10.3390/ph11040127
Imagawa S, Nakano Y, Obara N, et al. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB Journal. 2003;17:1742–1744. doi: 10.1096/fj.02-1134fje
Ghanim H, Abuaysheh S, Hejna J,et al Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis The Journal of Clinical Endocrinology & Metabolism, Volume 105, Issue 4, April 2020, Pages e1056–e1063,2020;105:4:1056-1063
Blum S, Shapir N, Miari R, et al. TARGT Gene Therapy Platform for Correction of Anemia in End-Stage Renal Disease. The New England Journal of Medicine. 2017. Jan 12;376(2):189-191. doi: 10.1056/NEJMc1606202.
